

PHARMACEUTICAL 2023

Larimar Therapeutics Inc. Rank 80 of 446









RealRate

PHARMACEUTICAL 2023





The relative strengths and weaknesses of Larimar Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Larimar Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Larimar Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 176% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	120,739
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,705
Liabilities, Non-Current	4,797
Other Assets	4,835
Other Compr. Net Income	-31
Other Expenses	0
Other Liabilities	0
Other Net Income	1,171
Other Revenues	0
Property and Equipment	831
Research and Development	24,250
Selling, General and Administrative Expense	12,276

Output Variable	Value in 1000 USD
Assets	126,405
Liabilities	15,502
Expenses	36,526
Revenues	0
Stockholders Equity	110,903
Net Income	-35,355
Comprehensive Net Income	-35,370
Economic Capital Ratio	219%

